AUROPHARMA.NSAUROPHARMA.NSNSE
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank50
3Y CAGR+19.1%
5Y CAGR+0.8%
Studio
Year-over-Year Change

Year-over-year research & development expense growth

3Y CAGR
+19.1%/yr
vs -26.6%/yr prior
5Y CAGR
+0.8%/yr
Recent acceleration
Acceleration
+45.7pp
Accelerating
Percentile
P50
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
2 yr
Consecutive growthRecovering
PeriodValue
202511.14%
20244.79%
2023-10.57%
20226.60%
202158.51%
202010.71%
201929.71%
201822.80%
201731.64%
201618.33%